Obsidian Therapeutics
Focus: Obsidian Therapeutics is a public cell and gene therapy biotech focused on oncology, based in Cambridge, MA with 51-200 employees. The company is early-stage with a single Phase 1/2 program in clinical development.
Profile data last refreshed Yesterday · AI intelligence enriched 2w ago
Funding Stage
PUBLIC
Employees
51-200
Open Jobs
0
About Obsidian Therapeutics
AI assessmentNot HiringNo open roles listed right now. Follow Obsidian Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.
Why Work Here
Data completeness
1/9 — Limited
Company HealthSolid
Pipeline
Early-stage
1 total
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
OBX-115
Tumor SkinClinical Trials (1)
NCT06060613Safety and Efficacy of OBX-115 in Advanced Solid Tumors
Phase 1/2Help build intelligence for Obsidian Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.